IQ-AI Limited ( (GB:IQAI) ) has provided an update.
IQ-AI Limited has published its audited financial statements for 2024, highlighting a revenue growth of over 20% and a significant reduction in losses. The company has formed a sales partnership with GE Healthcare and completed a successful post-year-end fundraising. IQ-AI’s product portfolio, including IB Clinic and IB Nimble, is expanding with new AI technologies and applications. The IB003 drug trial for glioblastoma shows promising interim results, suggesting potential survival benefits for patients, although further research is needed to confirm efficacy. The company is actively seeking partners to advance the development of IB003 and is monitoring legislative developments that could impact its drug development strategy.
More about IQ-AI Limited
IQ-AI Limited operates in the medical imaging and healthcare technology industry, focusing on advanced imaging software and artificial intelligence solutions. The company’s primary products include the IB Clinic suite, which offers various imaging platforms such as IB Neuro, IB Delta Suite, and IB ASL for neurological and whole-body imaging. Additionally, they provide StoneChecker and Liver Surface Nodularity applications for non-invasive assessments of kidney stones and liver health. IQ-AI is also involved in drug development, with a focus on the IB003 candidate drug for glioblastoma.
YTD Price Performance: -39.64%
Average Trading Volume: 616,907
Technical Sentiment Signal: Strong Buy
Current Market Cap: £2.08M
See more data about IQAI stock on TipRanks’ Stock Analysis page.